{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Goff PH"],"funding":["Sarcoma Foundation of America","ImmunoPrism","NCI NIH HHS","NIH"],"pagination":["1701-1711"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9953754"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(8)"],"pubmed_abstract":["<h4>Purpose</h4>To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.<h4>Experimental design</h4>Paired pre- and postneoadjuvant therapy specimens were retrospectively identified for 32 patients with STSs and analyzed by three modalities: multiplexed IHC, NanoString, and RNA sequencing with ImmunoPrism analysis.<h4>Results</h4>All 32 patients, representing a variety of STS histologic subtypes, received neoadjuvant radiotherapy and 21 (66%) received chemotherapy prior to radiotherapy. The most prevalent immune cells in the tumor before neoadjuvant therapy were myeloid cells (45% of all immune cells) and B cells (37%), with T (13%) and natural killer (NK"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells."],"pmcid":["PMC9953754"],"funding_grant_id":["L30 CA153318","P30 CA015704","R01 CA223498","R01CA244872","CA180380","R01 CA244872"],"pubmed_authors":["Goff PH","Jones RL","LaFranzo NA","Ricciotti R","McClanahan TK","Riolobos L","Smythe KS","LaFleur BJ","Kane GM","Cranmer LD","Wagner MJ","Pierce RH","Spraker MB","Pollack SM","Thompson MJ","Chen EY","Loggers ET","Kim TS","Blumenschein WM","Seo YD","Earls J","Murphy E","He Q","Mantilla JG","Flanagan KC","Campbell JS","Kim EY","Schaub SK","Zhang Y"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells.","description":"<h4>Purpose</h4>To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design.<h4>Experimental design</h4>Paired pre- and postneoadjuvant therapy specimens were retrospectively identified for 32 patients with STSs and analyzed by three modalities: multiplexed IHC, NanoString, and RNA sequencing with ImmunoPrism analysis.<h4>Results</h4>All 32 patients, representing a variety of STS histologic subtypes, received neoadjuvant radiotherapy and 21 (66%) received chemotherapy prior to radiotherapy. The most prevalent immune cells in the tumor before neoadjuvant therapy were myeloid cells (45% of all immune cells) and B cells (37%), with T (13%) and natural killer (NK","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-28T19:01:54.017Z","creation":"2025-02-19T00:13:46.53Z"},"accession":"S-EPMC9953754","cross_references":{"pubmed":["35115306"],"doi":["10.1158/1078-0432.ccr-21-4239","10.1158/1078-0432.CCR-21-4239"]}}